Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook

PD-1

  • You have access
    The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
    Jia Lu, Ting Li, Zhichao Liao, Hui Yu, Yongtian Zhao, Haixiao Wu, Zhiwu Ren, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Xiangchun Li, Kexin Chen, Jonathan Trent and Jilong Yang
    Cancer Biology & Medicine June 2022, 19 (6) 910-930; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0270
  • You have access
    Immunology and immunotherapy in breast cancer
    Vladimir Semiglazov, Andrey Tseluiko, Asel Kudaybergenova, Anna Artemyeva, Petr Krivorotko and Roman Donskih
    Cancer Biology & Medicine May 2022, 19 (5) 609-618; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0597
  • You have access
    Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events
    Weihong Zhang, Yuan Meng, Lin Yang, Meng Shen, Li Zhou, Runmei Li, Yang Wang, Weijiao Du, Yanjuan Xiong, Ying Han, Xinwei Zhang, Liang Liu and Xiubao Ren
    Cancer Biology & Medicine November 2021, 18 (4) 1109-1117; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0037
  • You have access
    Key questions about the checkpoint blockade-are microRNAs an answer?
    Mihnea Dragomir, Baoqing Chen, Xiao Fu and George A. Calin
    Cancer Biology & Medicine May 2018, 15 (2) 103-115; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0006
  • You have access
    PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
    Long Jia, Qi Zhang and Rongxin Zhang
    Cancer Biology & Medicine May 2018, 15 (2) 116-123; DOI: https://doi.org/10.20892/j.issn.2095-3941.2017.0086
  • You have access
    Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
    Mari Mino-Kenudson
    Cancer Biology & Medicine June 2016, 13 (2) 157-170; DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0009
  • You have access
    Immuno-oncology combinations: raising the tail of the survival curve
    Samuel J. Harris, Jessica Brown, Juanita Lopez and Timothy A. Yap
    Cancer Biology & Medicine June 2016, 13 (2) 171-193; DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0015
  • You have access
    Highlights of Miami winter symposium 2015: into the era of immunotherapy
    Wen Zhou
    Cancer Biology & Medicine March 2015, 12 (1) 68-69; DOI: https://doi.org/10.7497/j.issn.2095-3941.2015.0008

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2023 Cancer Biology & Medicine

Powered by HighWire